Company veteran Albert Bourla, who succeeded Read, will assume the additional role of chairman.
Read, 66, helped Pfizer weather patent expirations of several blockbusters, including cholesterol drug Lipitor, through dealmaking, expansion in emerging markets and cost cuts.
The drugmaker has since eschewed large, transformative deals because of confidence in the strength of its pipeline.
In July, Pfizer announced plans to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan NV, a move that will help the company focus on its innovative drugs that generate more profit.
Separately, the drugmaker reported positive data from a late-stage study testing its experimental atopic dermatitis treatment, abrocitinib.
The company's shares gained 0.6% at $36 in premarket trading.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila)
